Block Listing Application

RNS Number : 9212D

MaxCyte, Inc.

02 May 2017

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Block Listing Application

MaxCyte (AIM: MXCT, MXCR) provides notification that an application has been made to the London Stock Exchange for admission to AIM for a block listing of 1,000,000 ordinary shares of common stock of $0.01 each in the Company.

These shares, which will be identical in all respects with the existing issued shares of the common stock in the Company, will not be allotted immediately but rather will be allotted from time to time as and when options are exercised under the MaxCyte Long Term Incentive Plan.

It is expected that admission will become effective on or around 5 May 2017.

- ENDS -

For further information please contact:

MaxCyte	[phone]
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer
Nominated Adviser and Broker Panmure Gordon Freddy Crossley (Corporate Finance) Duncan Monteith Ryan McCarthy Tom Salvesen (Corporate Broking)	[phone]
Financial PR Advisor Consilium Strategic Communications	[phone] [e-mail]
Mary-Jane Elliott Chris Welsh Lindsey Neville

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines.  MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.   

For more information visit http://www.maxcyte.com/ 

 

END

 

 

ALSUGURWAUPMGPP